YLYueyang Lai

Yueyang Lai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yueyang Lai has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Haibo Cheng

    The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China

    3 shared publications
  • Changliang Xu

    Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, 210046, China; The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China

    2 shared publications
  • Jiani Tan

    Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, 210046, China; The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China

    2 shared publications
  • Lihuiping Tao

    Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, 210046, China; The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China

    2 shared publications
  • Minmin Fan

    Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, 210046, China; The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China

    2 shared publications
  • Rui Liu

    Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, National Administration of Traditional Chinese Medicine Key Laboratory for Chinese Medicine Resources Recycling Utilization, Nanjing University of Chinese Medicine, China

    2 shared publications

Latest Publications

  • Metabolic-circadian reprogramming mediates epithelial barrier destabilization during Euphorbia fischeriana toxicity and its mitigation by traditional milk processing

    by Ronglu Yu, Shurui Zhang, Enci Jiang, Errui Wang, Zhican Cheng, Hongli Yu, Jie Cao, Bingbing Liu, Yueyang Lai, Xinzhi Wang, et al.

  • Open Access

    Pinctada martensii Hydrolysate Modulates the Brain Neuropeptidome and Proteome in Diabetic (db/db) Mice via the Gut–Brain Axis

    by Jiayun Li, Yijun Lv, Yuanqing Wei, Xinzhi Wang, Shenghan Yan, Binyuan Zhao, Jipeng Sun, Rui Liu, Yueyang Lai

    Pinctada martensii hydrolysate (PMH) has been proved to have the effect of ameliorating disorders of glucose and lipid metabolism in db/db mice, but the mechanism of its hyperglycemia effect is still unclear. Bacterial communities in fecal samples from a normal control group, a diabetic control group, and a PMH-treated diabetes mellitus type 2 (T2DM) group were analyzed by 16S gene sequencing. Nano LC-MS/MS was used to analyze mice neuropeptides and proteomes. The 16S rDNA sequencing results showed that PMH modulated the structure and composition of the gut microbiota and improved the structure and composition of Firmicutes and Bacteroidetes at the phylum level and Desulfovibrionaceae and Erysipelatoclostridiaceae at the family level. Furthermore, the expressions of functional proteins of the central nervous system, immune response-related protein, and proteins related to fatty acid oxidation in the brain disrupted by an abnormal diet were recovered by PMH. PMH regulates the brain neuropeptidome and proteome and further regulates blood glucose in diabetic mice through the gut–brain axis. PMH may be used as a prebiotic agent to attenuate T2DM, and target-specific microbial species may have unique therapeutic promise for metabolic diseases.


  • Open Access

    Single-cell transcriptomics and Mendelian randomization reveal LUCAT1’s role in right-sided colorectal cancer risk

    by Zhihao Shang, Songyang Xi, Yueyang Lai, Haibo Cheng

    Background: Colorectal cancer (CRC) is a malignancy with high incidence and mortality rates globally, categorized into left-sided and right-sided CRC, each exhibiting significant differences in molecular characteristics, clinical manifestations, and prognosis.Methods: This study employed single-cell transcriptomic data and various bioinformatics approaches, such as two-sample Mendelian randomization, reverse Mendelian randomization, colocalization analysis, directed filtering, pseudotime analysis, and intercellular communication analysis. It analyzed cellular-level disparities between left-sided and right-sided CRC, identifying distinct subpopulations with characteristic variations. For these cells, two-sample Mendelian randomization was utilized to explore gene-to-one-sided CRC causality.Results: LUCAT1 was enriched in high-abundance monocyte subpopulations in right-sided CRC and demonstrated potential risk factor status through Mendelian randomization analysis. The specific single-nucleotide polymorphism (SNP) rs10774624 was associated with an increased risk of CRC. Moreover, metabolic pathway analysis revealed that LUCAT1+ monocytes exhibit lower communication activity in the tumor microenvironment and heightened activity in metabolic functions like glycosaminoglycan degradation. Its biological functions are related to the positive regulation of interleukin-6 production and NF-kappa B signaling, among others.Conclusion: This study confirmed a potential causal relationship between LUCAT1 and right-sided CRC risk through Mendelian randomization analysis. These findings provide novel insights into the pathogenesis of right-sided CRC and may aid in developing early detection and treatment strategies for right-sided CRC.


  • Open Access

    Arenobufagin enhances T-cell anti-tumor immunity in colorectal cancer by modulating HSP90β accessibility

    by Zhihao Shang, Yiping Fan, Songyang Xi, Shang Zhang, Weixing Shen, Lihuiping Tao, Changliang Xu, Jiani Tan, Minmin Fan, Hongyue Ma, et al.


  • Hyperglycemia effect of Pinctada martensii hydrolysate in diabetic db/db mice

    by Jiayun Li, Yuanqing Wei, Siying Huang, Shenghan Yan, Binyuan Zhao, Xinzhi Wang, Jipeng Sun, Tianbao Chen, Yueyang Lai, Rui Liu


  • Open Access

    HIPK3 Inhibition by Exosomal hsa-miR-101-3p Is Related to Metabolic Reprogramming in Colorectal Cancer

    by Lihuiping Tao, Changliang Xu, Weixing Shen, Jiani Tan, Liu Li, Minmin Fan, Dongdong Sun, Yueyang Lai, Haibo Cheng

    Background: Exosomes are extracellular vesicles secreted by most cells to deliver functional cargoes to recipient cells. MicroRNAs (miRNAs) constitute a significant part of exosomal contents. The ease of diffusion of exosomes renders them speedy and highly efficient vehicles to deliver functional molecules. Cancer cells secrete more exosomes than normal cells. Reports have showed that exosomal miRNAs of cancer cells facilitate cancer progression. Yet the complexity of cancer dictates that many more functional exosomal miRNAs remain to be discovered.Methods: In this study, we analyzed miRNA expression profiles of tissue and plasma exosome samples collected from 10 colorectal cancer (CRC) patients and 10 healthy individuals. We focused on hsa-miR-101-3p (101-3p), a profoundly up-regulated miRNA enriched in plasma exosomes of patients bearing CRC. We performed target analysis of 101-3p and pursued functional studies of this microRNA in two colorectal cancer cell lines, namely HCT116 and SW480.Results: Our results indicated that inhibiting 101-3p slowed cell growth and retarded cell migration in vivo in two colorectal cancer cell lines. Target analysis showed that Homeodomain-interacting protein kinase (HIPK3) is a target of miR-101-3p. HCT116 and SW480 cells stably overexpressing HIPK3 showed increased level of phosphorylated FADD, as well as retarded cell growth, migration, and increased sensitivity to 5-FU. In-depth analysis revealed increased mitochondrial membrane potential upon HIPK3 overexpression along with increased production of reactive oxygen species, number of mitochondria, and expression of respiratory complexes. Measurements of glycolytic parameters and enzymes revealed decreased level of glycolysis upon HIPK3 overexpression in these two cell lines. Xenograft model further confirmed a profoundly improved potency of the synergistic treatment combining both 5-FU and 101-3p inhibitor compared to 5-FU alone.Conclusion: This study unraveled an oncogenic nature of the exosomal 101-3p and suggested a relationship between the 101-3p-HIPK3 axis and metabolic homeostasis in colorectal cancer. Expression level of 101-3p is positively correlated with glycolytic capacity in CRC and therefore 101-3p itself is an oncomiR. Combining 101-3p inhibitor with chemotherapeutic agents is an effective strategy against CRC.